FOLH1 and pachyonychia congenita: Recent efforts have turned toward targeting prostate-specific membrane antigen (PSMA), a cell surface antigen expressed >1,000-fold in nearly all PC relative to normal prostate tissue 5,6, which allows targeting of both bone and soft tissue metastases 7.